The London Stock Exchange uses cookies to improve its website. The cookies for analytical purposes have already been set. For more details and how to manage cookies, please see our privacy and cookies policy.


AZN ASTRAZENECA PLC ORD SHS $0.25

ASTRAZENECA  Currency  GBX  Premium Equity Commercial Companies



 Page 10 of 11

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next |

Time/Date Code Headline Source Impact
07:00 06-Dec-2013 AZN European Commission Approves Fluenz Tetra RNS -0.60% Down
15:00 02-Dec-2013 AZN Blocklisting Interim Review RNS +0.55% Up
13:00 02-Dec-2013 AZN Total Voting Rights RNS +0.55% Up
13:42 22-Nov-2013 AZN XIGDUO POSITIVE CHMP OPINION FOR TYPE 2 DIABETES RNS +2.79% Up
07:00 19-Nov-2013 AZN NDA for Naloxegol accepted by US FDA RNS +3.24% Up
16:00 01-Nov-2013 AZN Total Voting Rights RNS -0.70% Down
13:45 01-Nov-2013 AZN Director/PDMR Shareholding RNS -0.70% Down
07:02 31-Oct-2013 AZN US Court Decision in Pulmicort Respules Litigation RNS -0.35% Down
07:01 31-Oct-2013 AZN Marc Dunoyer Appointed Chief Financial Officer RNS -0.35% Down
07:00 31-Oct-2013 AZN 3rd Quarter Results RNS -0.35% Down
09:00 30-Oct-2013 AZN Notice of Results RNS +0.38% Up
07:00 30-Oct-2013 AZN ASTRAZENECA ADVANCES BENRALIZUMAB TO PHASE III RNS +0.38% Up
07:00 22-Oct-2013 AZN AstraZeneca starts phase III study for selumetinib RNS +3.01% Up
07:00 15-Oct-2013 AZN Medimmune acquires Spirogen RNS +0.19% Up
07:00 07-Oct-2013 AZN MedImmune completes Amplimmune acquisition RNS -1.26% Down
16:00 01-Oct-2013 AZN Total Voting Rights RNS -1.19% Down
07:01 30-Sep-2013 AZN MAA FOR OLAPARIB ACCEPTED BY EMA RNS -0.81% Down
07:00 27-Sep-2013 AZN MAA APPLICATION FOR NALOXEGOL ACCEPTED RNS -0.49% Down
12:54 20-Sep-2013 AZN Fluenz Tetra receives positive CHMP opinion in EU RNS -0.50% Down
07:00 04-Sep-2013 AZN Starts phase III clinical programme for olaparib RNS -1.24% Down

 Page 10 of 11

Previous | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | Next |

Price changes are calculated on the basis of the following formula: [ avg(x) - avg(y)] / avg(y) where:
x = instrument's 7 closing prices after the news has been released, including the day of the release of the news
y = instrument's latest 7 closing prices before the news was released

Please note that the news releases are only one of the multiple factors that could have had an impact on the change in the security’s price over the time period analysed by the News Analysis tool. Where data are insufficient the graph does not show any price change and the table below the graph displays a blank " - " next to the line indicating the RNS issue.


ASTRAZENECA share - news analysis

The Exchange accepts no responsibility for the content of the website you are now accessing or for any reliance placed by you or any person on the information contained on it.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds.

You are accessing the London Stock Exchange Annual Report Service powered by PrecisionIR.

The Exchange accepts no responsibility for the content of the reports you are now accessing or for any reliance placed by you or any person on the information contained therein.

By allowing this link the Exchange does not intend in any country, directly or indirectly, to solicit business or offer any securities to any person.

You will be redirected in five seconds